Диссертация (1173577), страница 50
Текст из файла (страница 50)
Pharmaceutical pricing: a review of proposals to improve accessand affordability of prescription drugs. 19 Ann Health Law. 2010. P. 19.83.Troller A. KurzreferatgehaltenamSymposiumUberdieImmaterialgtiterrechte im Internationalen Privatrecht (Munich, West Germany, Apr. 18,1975); Troller, supra note 5, at 1135.84.Ullrich H. VI Abschnitt. Kartellverfahrensverordnung in Ulrich Immenga,Ernst-Joachim Mestmäcker.85.Ulmer E. Intellectual Property Rights and the Conflict of Laws 99 –112,1978.
(English translation of E. ULMER, DIE IMMATERIALG"JTERRECHTE IMINTERNATIONALEN PRIVATRECHT (1975)).86.UNCTAD/ITE ‘The TRIPS agreement and Developing Countries’ (1996),p. 48. URL: http://www.unctad.org/en/docs/ite1_en.pdf (дата обращения: 30.04.2017).23987.UNCTAD/ICTSD Resource Book on TRIPS and Development (CambridgeUniversity Press, 2005). P. 529.88.Young R.J. (2003). The construction of product-by-process calims – Astudy in enlightened compromise. OJ EPO, Special Edition 2, p. 20.89.Vestergaard-Jensen J., Hamborg R., Simonsen E. Denmark // InternationalLicensing / Ed. by Campbell D. L., 2005 (Rel.
13 - March 2004). P. 46.90.Voet M. The Generic Challenge: Understanding Patents, FDA &Pharmaceutical Life-Cycle Management, 2nd Edition,Brown Walker Press, Boca Raton,2008. P. 123.91.Vaitsos C. V. The Revision of the International Patent System: LegalConsiderations for a Third World Position” (1976) 4(2) World Development. P. 85 –88.92.ofWertheimer A.I., Santella T.M. Pharmaceutical Evolution, The AdvantagesIncrementalInnovationinDrugDevelopment Aprilhttps://cei.org/studies-issue-analysis/pharmaceutical-evolution7,(дата2009.URL:обращения:30.04.2017).93.Wettbewerbsrecht Kommentar zum Europäischen Kartellrecht, 4.
Auflage,München, Verlag C. H. Beck, 2007.94.Whish R. Competition Law, Oxford, Oxford University Press, 2008, p.95.WIPO Intellectual Property Handbook: Policy, Law and Use, Publication786.No. 489 (E), 2004, Second Edition, 488 p.96.World Trade Organization (WTO), Understanding the WTO, p. 19. URL:<http://www.wto.org/english/thewto_e/whatis_e/tif_e/understanding_e.pdf>.(датаобращения: 30.12.2016).Материалы судебной практики1.Постановление Президиума Высшего Арбитражного Суда РоссийскойФедерации от 16.06.2009 № 2578/09 по спору «Новартис АГ» против ЗАО «ФармСинтез».2402.Постановление Девятого арбитражного апелляционного суда от15.10.2014 № 09АП-38389/2014-ГК по делу № А40-14800/14.3.Постановление Девятого арбитражного апелляционного суда№09АП-1634/2016-ГК от 27 апреля 2016 года по делу № А40-30124/2015 // URL:http://kad.arbitr.ru/Card/9a8b34c2-8325-4866-ab8c-69f4c9038686 (дата обращения:30.04.2017).4.Решение Арбитражного суда Московской области от 02 ноября 2015года по делу № А41-46966/15 // URL: http://kad.arbitr.ru/Card/a2e5bdcd-6db7-478886aa-d792024c5d3e (дата обращения: 30.04.2017).5.Решение Арбитражного суда Московской области от 02 ноября 2015года по делу № А41-46966/15 // URL: http://kad.arbitr.ru/Card/a2e5bdcd-6db7-478886aa-d792024c5d3e (дата обращения: 30.04.2017).6.Постановление Президиума Высшего Арбитражного Суда РоссийскойФедерации№2578/09от16июня2009г.//URL:http://kad.arbitr.ru/Card/150265fb-e3b9-4702-b9ec-1d555ef03a0e (дата обращения:30.04.2017).7.Заключение Палаты по патентным спорам от 01.02.2013 (Приложениек решению Роспатента от 26.04.2013 по заявке № 2008103699/04) «Об отменерешения Роспатента и выдаче патента Российской Федерации на изобретение».8.Решения Большой апелляционной палаты Европейского патентноговедомства № G 2/88, № G 1/98 URL: http://www.epo.org/law-practice/case-lawappeals/eba/number.html (дата обращения: 30.04.2017).9.Bayer Corporation v.
Natco Pharma Ltd., Order No. 19/2013 (IntellectualProperty Appellate Board, Chennai), (Cited at 24 Jan, 2016). Available atwww.ipabindia.in/Pdfs/Order-19-2013.pdfBDR Pharmaceuticals International Pvt. Ltd.v. Bristol-Myers Squibb Company. C.L.A. No. 1 of 2013. October 29, 2013. URL:http://ipindia.nic.in/iponew/Order_30October2013.pdf (дата обращения: 30.04.2017).10.Board of Appeal Decision T 296/93 of 28 July 1994 – HBV antigenproduction/BGIOGENINC.URL:https://www.epo.org/law-practice/case-law-appeals/recent/t980091eu1.html (дата обращения: 30.04.2017).24111.Board of Appeal Decision T 91/98 of 29 May 2001 – Antiviralnucleoside/Wellcome.12.Board of Appeal Decision T 870/04 of 11 May 2005 – BDPIPhospharase/MAX-PLANCK.13.Board of Appeal Decision T 604/04 of 16 March 2006 – PF4Areceptors/Genentech.14.Board of Appeal Decision T 898/05 of 7 July 2006 – Hematopoieticreceptor/Zymogenetics.15.Board of Appeal Decision T 1452/06 of 10 May 2007 – Serine Protease /Bayer.16.BoardofAppealDecisionT18/09of21October2009–Neutrokine/Human Genome Sciences.17.Case C-368/96 The Queen v The Licensing Authority established by theMedicines Act 1968 (acting by The Medicines Control Agency), ex parte Generics(UK)LtdandOthers.URL:http://curia.europa.eu/juris/showPdf.jsf;jsessionid=9ea7d2dc30dbe7249ce801c648dbaf4cfd341a24b280.e34KaxiLc3qMb40Rch0SaxuKb3n0?text=&docid=101225&pageIndex=0&doclang=EN&mode=req&dir=&occ=first&part=1&cid=27114 (дата обращения:30.04.2017).18.Case Law of the Boards of Appeal of the European Patent Office, 6thedition, Munich 2010, p.
162.19.Canadian Federal Court Decision, AstraZeneca Canada Inc. v. Apotex Inc.,2010 FC 714 URL: http://decisions.fct-cf.gc.ca/fc-cf/decisions/en/item/58357/index.do(дата обращения: 30.04.2017).20.Court of Justice of the European Union (CJEU), Cases C-207/03 Novartisv. Comptroller General and C-252/03 Ministre de l'Economie v MilleniumPharmaceuticals, 2005, RPC 33, URL:http://curia.europa.eu/juris/liste.jsf?num=C-207/03&language=en (дата обращения: 30.04.2017).24221.Decision of 12 January 1984, OJ EPO 1984, 164 – Pyrrolidine-Derivatives/Hoffmann-La Roche.
T 128/82 OJ EPO 1984 (“T 128/82 PyrrolidineDerivatives”) p. 164.22.Decision G 2/08 of 12 January 1984, OJ EPO 1984, 164 – Pyrrolidine-Derivatives/HOFFMANN-LA ROCHE. T 128/82 OJ EPO 1984 (“T 128/82Pyrrolidine-Derivatives”) p. 164.23.Decision of 16 January 2008 – Stimulation of beta cell proliferation /NovoNordisk.24.Decision G 2/06 of the Enlarged Board of Appeal of 25 November 2008,OJ EPO 2009, 306 – Use of embryos/WARF.25.Decision of 17 December 2009, GPUR Int. 2009, 236 – NeuraleVorläuferzellen = 41 IIC 853 (2010) – Neural precursor cells/ Brüstle’s patent(Greenpeace v. Oliver Brüstle).26.Enlarged Board of Appeal Decisions G 1/83, G 5/83, G 6/83 of 5December 1984 (OJ EPO 1985, 60, 64, 67).27.– The G 5/8 Second Medical Indication /Eisai and G-2/08 DosageRegime/ABBOTT RESPIRATIRY Cases’,IIC.28.Enlarged Board of Appeal Decision G 2/08, OJ EPO 2010, 456 – Dosageregime/ABBOTT RESPIRATORY (“G 2/08 Dosage regime”), [5.8], [5.9.1], [5.10.3] //URL:http://www.epo.org/law-practice/legal-texts/html/caselaw/2016/e/clr_i_c_7_2_3.htm (дата обращения: 30.04.2017).29.European Court of Justice in the Case 368/96, R v The Licensing Authorityestablished by the Medicines Act 1968 [1999] ECR I-7967.30.Federal Trade Commission v.
Watson Pharmaceuticals, Inc., CPI AntitrustChronicle June 2012 (2) WL 1427789, April 25, 2012.31.House of Lords decision of 21 October 2004 – Kirin-Amgen Inc. v.Hoechst Marion Roussel Ltd., (2005) RPC 169.32.OfficialEuropean Court of Justice Case C-34/10, Oliver Brüstle v Greenpeace e.v.,Unpublished.ReportesinIIC,43,711http://curia.europa.eu/juris/liste.jsf?language=en&num=C-34/10.(2012)//URL:24333.Supreme Court of the United States, Merck KGaa v. Integra Lifesciences I,Ltd., No.
03—1237, 545 U.S. 193 (2005).34.U.S. Supreme Court, Graham et al. v. John Deere Co. of Kansas City et al,383 U.S 1 (1966). URL: https://supreme.justia.com/cases/federal/us/383/1/case.html(дата обращения: 08.09.2017).35.U.S. Supreme Court, KSR International v.
Teleflex, 550 U.S. _; 127 S.Ct.1727 (2007). URL: https://www.supremecourt.gov/opinions/06pdf/04-1350.pdf (датаобращения: 08.09.2017).36.United States Court of Appeals, Federal Circuit. Aug. 1, 2003, Shering vGeneva pharmaceutical. 339 F3d 1373 (FCCA 2003).37.United States Court of Appeals, Federal Circuit, Abbott Laboratories v.Sandoz, Inc.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
